Defective Medical Device and Pharmaceutical Injury Lawyer in Phoenix, Arizona

How Drug and Device Claims Differ From Ordinary Injury Claims

A defective drug or medical device claim is a product liability claim, governed in Arizona by A.R.S. § 12-681 and the sections that follow. That statutory scheme reaches anyone in the chain of distribution — the manufacturer, and in defined circumstances a distributor or seller — and it supports both strict liability and negligence theories. Strict liability asks whether the product was in a defective condition unreasonably dangerous when it left the defendant's control. Negligence asks whether the defendant's own conduct in designing, manufacturing, testing, labeling, or monitoring the product fell below reasonable care. The general framework is the same one described on our product liability page, which is the parent topic for everything on this page.

What makes drugs and devices different is not the legal test. It is the surrounding structure.

First, these products are federally regulated. The FDA reviews, clears, or approves them, and manufacturers report adverse events into federal databases. That regulatory record becomes evidence, and it also raises questions about federal preemption that do not exist in an ordinary consumer-product case.

Second, a prescriber sits between the manufacturer and the patient. Warnings about a prescription drug or an implanted device are directed to the physician rather than the consumer, which changes how a failure-to-warn claim is structured. That is the learned intermediary doctrine, discussed below.

Third, the injury is often latent. A device that fractures, migrates, corrodes, or sheds material may do so years after implantation, and a medication's harm may be identified only after long-term use. That timing interacts with Arizona's limitations and repose statutes in ways that need case-specific analysis.

Fourth, causation is medically complex. The patient was already sick or injured — that is why the product was used — so the defense will attribute the outcome to the underlying condition, the surgery, or the disease process rather than the product. Establishing that the product caused the harm typically requires medical records, explant analysis where a device was removed, regulatory history, and qualified expert opinion.

We evaluate defective drug and device claims and, where appropriate, coordinate with national litigation counsel. We do not claim experience or results in any particular product litigation, and nothing on this page should be read as a statement about any specific product or manufacturer.

The Three Defect Types Applied to Drugs and Devices

Arizona product liability law recognizes three ways a product can be defective. Each looks different when the product is something swallowed, injected, or implanted.

A design defect means the product line itself is unreasonably dangerous as designed, even when manufactured exactly to specification. In the device context, the argument is typically that the geometry, the materials, or the failure mode created a risk that a feasible alternative design would have avoided — a component that fatigues and fractures under normal physiologic loading, a material that degrades or corrodes in the body, a device that migrates from its intended position, or an anchoring method that erodes surrounding tissue. In the pharmaceutical context, design theories tend to focus on formulation, dose, or delivery mechanism, and they are the most likely of the three to encounter preemption arguments.

A manufacturing defect means the individual unit departed from the manufacturer's own design and specifications. Here the comparison is between the unit that injured the patient and what the specifications required: a contaminated or misfiltered lot, a sterility breach, an out-of-tolerance component, an incorrect concentration or potency, a labeling or packaging mix-up, or a software or firmware defect in a programmable device. Manufacturing-defect claims are often the most concrete, because the manufacturer's own batch records, quality-control documentation, and lot history define the standard the unit failed to meet.

A warning or labeling defect means the risks were not adequately communicated to those who needed the information. This is the most common theory in drug and device litigation. It covers a known risk omitted from the label entirely, a risk disclosed in language too vague or buried to convey its actual severity or frequency, inadequate instructions for use, implantation, or removal, a missing contraindication for a patient population, and failure to update the warning as post-market adverse-event data accumulated. Because a manufacturer's duty to warn is continuing, what the company learned after launch — and when it learned it — is frequently the center of the case.

As historical illustrations only, categories such as surgical mesh implants, IVC blood-clot filters, and recalled medications have generated litigation in the United States under these theories. They are referenced here to show how the defect categories work in practice. They are not statements about any current matter, and this firm does not represent them as active case types.

The Learned Intermediary Doctrine: Warnings Run to the Prescriber

For most consumer products, the manufacturer must warn the consumer. Prescription drugs and prescription-only medical devices are treated differently under the learned intermediary doctrine, which Arizona courts apply.

Under that doctrine, the manufacturer's legal duty to warn is owed to the prescribing physician rather than directly to the patient. The reasoning is that the physician is a trained professional who evaluates the individual patient, weighs risks against benefits, and communicates what matters to that patient. Warning the physician adequately is therefore treated as discharging the duty.

This has three practical consequences for a failure-to-warn claim.

The first is the content of the warning. The question becomes whether the information the manufacturer gave physicians — through the label, package insert, instructions for use, safety communications, and what its sales representatives told them — accurately conveyed the risk the manufacturer knew or should have known about at the relevant time.

The second is causation, and it is where these claims are usually contested. The plaintiff generally must show that an adequate warning would have changed the outcome. That evidence typically comes from the prescriber's own testimony about what they knew, what they were told, what they relied on, and what they would have done differently with complete information. This is why prescriber records and the manufacturer's promotional and detailing materials matter so much.

The third is scope. The doctrine addresses the duty to warn. It does not eliminate design defect claims, manufacturing defect claims, or negligence claims about testing and post-market surveillance. A manufacturer that gave physicians a flawless label can still face a claim that the product itself was defectively designed or manufactured.

There are recognized limits and exceptions to the doctrine in various jurisdictions, and whether one applies is a case-specific question rather than something to assume from a general description.

Federal Preemption in Plain Language

One question comes up in almost every consultation about a drug or device: if the FDA approved it, can it still be the basis of a lawsuit?

The short answer is that FDA involvement does not automatically bar state-law injury claims. The longer answer is that federal preemption analysis varies significantly depending on what kind of product is involved and what regulatory pathway it went through, and it is one of the first issues that gets analyzed in these cases.

At an overview level, the landscape breaks down roughly this way. Brand-name prescription drugs, generic drugs, and medical devices are each analyzed differently. Within devices, the pathway matters: devices that go through the most rigorous premarket approval process are treated differently from devices cleared through the pathway based on substantial equivalence to an existing product. A central concept across all of these is whether the manufacturer could have independently done the thing the lawsuit says it should have done — for example, strengthened a warning — without violating federal law. Where federal law left the manufacturer room to act, claims are more likely to survive; where federal law required exact sameness or precluded unilateral change, the analysis is harder.

The practical takeaway is not a rule you can apply to your own situation from a webpage. It is that the answer depends on the specific product, the specific regulatory pathway, and the specific theory pleaded, and that being told "the FDA approved it, so there is nothing you can do" is not a reliable answer. This analysis is claim-specific and is part of what an evaluation covers.

Deadlines: Two-Year Limitations, Discovery Rule, and the 12-Year Repose

Two separate clocks apply to Arizona product claims, and they work differently. Confusing them is one of the more costly mistakes in this area.

The statute of limitations for personal injury is two years under A.R.S. § 12-542, measured from when the cause of action accrues. Accrual is not always the date of the surgery or the first dose. Arizona applies a discovery rule, under which a claim accrues when the plaintiff knows or by the exercise of reasonable diligence should know of the injury and its cause. That rule matters enormously for drug and device injuries, which are frequently latent: a patient who has been told for years that ongoing pain is a normal surgical result, or that a symptom is part of the underlying disease, may not have the information that starts the clock. Discovery-rule questions are fact-intensive and are resolved case by case.

The statute of repose is different. A.R.S. § 12-551 provides that a product liability action must be commenced within twelve years after the product was first sold for use or consumption, subject to exceptions stated in the statute, including where the product's useful safe life had not expired and where an express warranty of a longer period applies. A repose period is not a limitations period. It runs from the sale of the product rather than from the injury, and it can extinguish a claim in theory before the harm is even discovered. For an implanted device, the relevant date is generally tied to the sale of that product rather than to the patient's symptoms, which is why implant dates and product identification are gathered early.

Other rules can adjust the analysis: claims by minors are treated differently, wrongful death claims are analyzed under their own framework, and a claim involving a public entity or public employee — a public hospital or clinic, for example — triggers a written notice of claim within 180 days under A.R.S. § 12-821.01 and suit within one year under A.R.S. § 12-821.

Because the interaction of these rules depends on when the product was sold, when it was used or implanted, when the injury appeared, and when its cause became knowable, there is no single deadline to quote here. Get case-specific advice promptly rather than assuming a date.

Mass Torts, MDLs, and Why Your Claim Stays Your Claim

When many people are injured by the same product, the cases are usually organized rather than litigated one at a time in isolation. Two structures get confused constantly, and the difference matters.

A class action treats a large group as a single unit. One or a few representatives litigate on behalf of everyone, a court certifies the class, and a resolution binds all members who do not opt out. Class treatment works best where the harm is uniform and easily measured, which is why it is more common in economic-loss and consumer cases than in personal injury.

A mass tort keeps the cases individual. Each injured person files their own lawsuit with their own facts, their own medical history, and their own damages. When many such federal cases involve common questions, the Judicial Panel on Multidistrict Litigation may transfer them to a single federal judge for coordinated pretrial proceedings — an MDL. State courts have analogous consolidation procedures.

An MDL exists for efficiency, not to merge the claims. General causation, corporate discovery, document productions, and company-witness depositions are handled once for everyone instead of repeated in every case. Bellwether cases are tried to give both sides information about how juries respond to the evidence. Individual issues — your medical history, your specific product and lot, your prescriber, your injuries, your losses — remain individual, and your damages are evaluated on your own facts.

What this means practically for someone in Arizona is that participating in coordinated litigation does not turn your injury into an average. It also means the choice of counsel still matters, because someone has to develop your individual record: the product identification, the implant or prescription history, the treating providers, and the damages proof that only apply to you.

We evaluate defective drug and device claims and, where appropriate, coordinate with national litigation counsel who handle the coordinated proceedings. That arrangement is explained in writing before anything is filed, and it does not change the fee the client agreed to.

What to Preserve, and Why It Decides Cases

Identification is the threshold problem in drug and device cases. Before anyone can analyze a defect, the exact product must be identified: the manufacturer, the model, the lot or batch, and the date it was used or implanted. Cases fail on identification more often than on the merits.

What to keep, starting today:

• The product itself, if you still have it. Do not discard it, return it to the manufacturer or pharmacy, or send it anywhere without advice, even if you are asked to.
• Packaging, boxes, blister packs, bottles with labels intact, inserts, and instructions for use. Lot and batch numbers usually live only on the packaging.
• Any explanted device. If a device is being removed surgically, ask the surgeon and hospital in writing, before the procedure when possible, to preserve the explanted device and not to return it to the manufacturer. Ask that it be handled and stored so it can later be examined.
• Pharmacy records and prescription history, including refill records, which establish dosing and duration.
• The implant card, device identification card, or serial and UDI information given to you after a procedure.
• Operative reports, implant logs, device stickers placed in the chart, imaging, and pathology.
• Recall notices, safety communications, and any letter from the manufacturer, the pharmacy, the surgeon, or the hospital.
• Your own timeline: when the product was used or implanted, when symptoms started, what you were told about them, and by whom.

A written preservation request sent early to the hospital, surgical center, and pharmacy is often what keeps the physical evidence available. Recall notices deserve one caution: a recall is useful evidence of a known problem, but it does not by itself establish that the product caused a particular injury, and there is no substitute for the medical proof.

We evaluate defective drug and device claims. The consultation is free, these matters are handled on a contingency fee, and there is no fee unless there is a recovery. Call Saguaro Injury Law at (602) 217-0000.